Jaffar, Shabbar

Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021

Ng, M., Gakidou, E., Lo, J., Abate, Y. H., Abbafati, C., Abbas, N., Abbasian, M., Abd ElHafeez, S., Abdel-Rahman, W. M., Abd-Elsalam, S., et al. (2025) · The Lancet

Obesity, Physical Activity, DietDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,151

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Hay, S. I., Ong, K. L., Santomauro, D. F., A, B., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abaraogu, U. O., Abate, B. B., Abbafati, C., et al. (2025) · The Lancet

Global Health and EpidemiologyCardiovascular Health and Risk Factors

Cited by 916

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Naghavi, M., Kyu, H. H., A, B., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abafita, B. J., Abaraogu, U. O., Abbafati, C., Abbasi, M., et al. (2025) · The Lancet

Insurance, Mortality, Demography, Risk ManagementGlobal Health and Epidemiology

Cited by 595

Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes

Jarvis, J. N., Bicanic, T., Loyse, A., Namarika, D., Jackson, A., Nussbaum, J. C., Longley, N., Muzoora, C., Phulusa, J., Taseera, K., et al. (2014) · Clinical Infectious Diseases

Fungal Infections and StudiesInfectious Diseases and Tuberculosis

Cited by 367

Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients

Bicanic, T., Muzoora, C., Brouwer, A. E., Meintjes, G., Longley, N., Taseera, K., Rebe, K., Loyse, A., Jarvis, J., Bekker, L., et al. (2009) · Clinical Infectious Diseases

Fungal Infections and StudiesAntifungal resistance and susceptibility

Cited by 227

Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries

Loyse, A., Burry, J., Cohn, J., Ford, N., Chiller, T., Ribeiro, I., Koulla-Shiro, S., Mghamba, J., Ramadhani, A., Nyirenda, R., et al. (2019) · The Lancet Infectious Diseases

Fungal Infections and StudiesAntifungal resistance and susceptibility

Cited by 90

Short-course High-dose Liposomal Amphotericin B for Human Immunodeficiency Virus–associated Cryptococcal Meningitis: A Phase 2 Randomized Controlled Trial

Jarvis, J. N., Leeme, T. B., Molefi, M., Chofle, A. A., Bidwell, G., Tsholo, K., Tlhako, N., Mawoko, N., Patel, R. K. K., Tenforde, M. W., et al. (2019) · Clinical Infectious Diseases

Fungal Infections and StudiesAntifungal resistance and susceptibility

Cited by 86

A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis

Jackson, A. T., Nussbaum, J. C., Phulusa, J., Namarika, D., Chikasema, M., Kanyemba, C., Jarvis, J. N., Jaffar, S., Hosseinipour, M. C., van der Horst, C., et al. (2012) · AIDS

Fungal Infections and StudiesAntifungal resistance and susceptibility

Cited by 86